In our previous series of studies, we found that Srx preferentially interacts with Prx4 due to its intrinsically higher binding affinity, and the Srx–Prx4 axis contributes to the activation of oncogenic signaling pathways in different types of human cancer [9,11,12]. The gene discussed is PRDX4; the disease is cancer.